Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 1/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.32 |
| ▸ | FEN1 | P39748 | 3/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29821567 | 0.90 | ROCK2 (0.36) | DGAT1ALOX5APFEN1ROCK2 | |
| SCHEMBL20587522 | 0.90 | ROCK2 (0.36) | DGAT1ALOX5APFEN1ROCK2 | |
| SCHEMBL29822120 | 0.87 | AXL (0.37) | AXLDGAT1ALOX5APFEN1 | |
| SCHEMBL20589155 | 0.87 | AXL (0.37) | AXLDGAT1ALOX5APFEN1 | |
| SCHEMBL4248870 | 0.85 | S1PR4 (0.38) | DGAT1 | |
| SCHEMBL30173497 | 0.82 | DGAT1 (0.33) | DGAT1ALOX5APFEN1 | |
| SCHEMBL25793370 | 0.81 | DGAT1 (0.37) | DGAT1 | |
| SCHEMBL20588360 | 0.81 | DGAT1 (0.35) | DGAT1ALOX5APFEN1 | |
| SCHEMBL21632538 | 0.80 | DGAT1 (0.45) | DGAT1ALOX5APFEN1 | |
| SCHEMBL20589206 | 0.79 | DGAT1 (0.37) | DGAT1ALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1761268-A4 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2009-07-08 | — | — | EP | disclosed |
| US-7439246-B2 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-10-21 | — | — | US | disclosed |
| US-7439246-B2 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-10-21 | — | — | US | disclosed |
| EP-1761268-A2 | PYRROLOTRIAZINE KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2007-03-14 | — | — | EP | disclosed |
| US-7173031-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| US-7173031-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| US-20060211695-A1 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-09-21 | — | — | US | disclosed |
| WO-2006004833-A2 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-01-12 | — | — | WO | disclosed |
| US-20060004006-A1 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-05 | — | — | US | disclosed |
| US-20050288290-A1 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288290-A1 | Fused heterocyclic kinase inhibitors | MAP3K20, MAP3K19, ABL1 | AXL 452/4885DGAT1 3798/4885ALOX5AP 4670/4885 |
| US-20060004006-A1 | Pyrrolotriazine kinase inhibitors | MAP3K5, MAP3K15, MAP4K2 | AXL 880/4885DGAT1 3356/4885ALOX5AP 2755/4885 |
| US-20060211695-A1 | Fused heterocyclic kinase inhibitors | MAP3K20, MAP3K19, ABL1 | AXL 452/4885DGAT1 3798/4885ALOX5AP 4670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.